News Daily News FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy Michael O'Riordan April 29, 2022
News Daily News Cardio-Obstetrics Merits Better Training, Wider Uptake: Survey Caitlin E. Cox April 26, 2022
News Daily News Don’t Rule Out CABG for Elderly Patients With Multiple Comorbidities Michael O'Riordan April 25, 2022
News Daily News CVD Hospitalizations Spiked in Aftermath of 2020 US Election Michael O'Riordan April 22, 2022
News Daily News Cardiac Complications Higher After COVID-19 Than Vaccination Shelley Wood April 14, 2022
News Conference News ACC 2022 No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3 Michael O'Riordan April 13, 2022
News Conference News ACC 2022 DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF L.A. McKeown April 08, 2022
News Conference News ACC 2022 QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis L.A. McKeown April 07, 2022
News Conference News ACC 2022 POISE-3: Two Perioperative BP Strategies Give Similar Results in Noncardiac Surgery Todd Neale April 06, 2022
Presentation ACC 2022 A Cluster-Randomized PRagmatic Trial Aimed At ImprOving Use Of Guideline Directed Medical Therapy In OutPatienTs With Heart Failure: PROMPT-HF Presenter: Tariq Ahmad April 04, 2022
Presentation ACC 2022 SODIUM-HF: Study Of Dietary Intervention Under 100 Mmol In Heart Failure Presenter: Justin Ezekowitz April 04, 2022
News Conference News ACC 2022 Most Infected Cardiac Implanted Electronic Devices Not Removed Fast Enough Michael O'Riordan April 04, 2022
News Conference News ACC 2022 CHAP: Better Blood Pressure Control, Better Pregnancy Outcomes Michael O'Riordan April 02, 2022
News Conference News ACC 2022 SODIUM-HF: No Impact of Tighter Dietary Salt Restriction on Death or Hospitalization L.A. McKeown April 02, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Daily News Prognosis of Myocarditis Following COVID-19 Vaccination ‘Favorable’ Michael O'Riordan March 28, 2022